Advertisement
Advertisement
U.S. markets open in 4 hours 40 minutes
Advertisement
Advertisement
Advertisement
Advertisement

TRACON Pharmaceuticals, Inc. (TCON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.3600+0.0500 (+2.16%)
At close: 04:00PM EST
Advertisement
Sign in to post a message.
  • L
    Lutz
    Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) in Each Cohort Satisfied the Bar for Futility and Supports Continued Accrual.

    meets the bar = 11%????
  • T
    Tartiaboy
    I see a lot of discouraged posters here right now. I am not one of them.
  • J
    Joan
    #1 Bullish Trade For 2022 🔥🔥🔥

    https://bullish-trades.com/top-trade-idea
    Bullish
  • L
    Lutz
    Something coming now?
  • S
    Steven
    Great data … 5 dollar holler coming
  • S
    Steven
    Buy the dip
    There was not negative news
  • w
    wallstreetboss
    (RVPH) $2.95-- MCap $42 m--Cash $34 million --A Phase 3 biotech with MONSTER Pipeline targeting multiple blockbuster indications like Alzheimer ,Parkinson ,Depression ,ADHD and so forth / under radar low float stock = CHEAPEST Biotech out there with potential to run like SAVA which went from $3 to $130+ ...GLTA !!!
  • T
    Tartiaboy
    I am looking for at least 4/36 responses in the Envasarc efficacy reveal later this month.
  • b
    bc322032
  • T
    Tartiaboy
    Between now and EOY expect a top line data readout on the first Envasarc futility analysis. I am expecting a good report.
  • T
    Thomas
    Envafolimab approved in China 11/27/21. Sorry can’t post link.
  • P
    Peter
    Mr. Billy, seriously u gonna ride this thing back down again and ride it through another 10 for 1 ?? my heart is with u. Hope you had a good Christmas and who knows FDA approval... Happy New Year's.
  • D
    Dr Jim P. , MD
    $AGEN conversation
    Based on the $GILD $RCUS deal, you might be interested in:

    Stocks researching TIGIT:
    $AGEN, $BGNE, $CGEN, $ITOS, $MREO, $PHIO, $RCUS

    Stocks researching CD73:
    $AGEN, $CALA, $CRVS, $IMAB, $IPHA, $ORIC, $RCUS, $TCON
  • L
    Lutz
    The ORR by BICR in each cohort satisfied the prespecified futility rule.

    will there be anything more detailed?
  • P
    Peter
    taking losses for my year end. NEVER TO RETURN.
    Good luck Billy. Loosing money at a Casino is wwwwaaaayyy more fun
  • L
    Lutz
    @ Billys question : why envafolimab has not been approved in China?
    To my knowledge NDA approval process in China takes on average 3 years. With fast track for enva and guessing 18months process time I expect approval not before April 2022. Hence my guess It could come in May 2022. So not worried here as Tartia is.
  • B
    Billy
    to my fellow long time posters, so sorry for bad news today, feel as if we got duped, staying in, not giving it away for pennies, good luck to you all in your future trades, my trading days are done, too many losses, too much stress, too much deceit
  • L
    Lou
    TODAY, 05/10/2018---NEEDHAM COVERS WITH A BUY AND AN $8.00 TARGET +300% UPSIDE
    THE LISBON JUNE 10-14 CONFERENCE TCON WILL PUT OUT POSITIVE RESULTS ON 102 CONFIRMED BY THE CEO
    THIS IS THE START OF THE MOVE UP.....TIME TO BUY IN AND STAY
  • J
    J0E
    De122 opens tcon up to $145 million in milestone payments and 200-300million a year profits from peak sales at Santen once commercialized... we have that opportunity from a $15 million dollar company... and don’t forget we also have a possible double or triple in value over night if j&j opt in... from the 45 million dollar payment tcon would receive they also can have 137.5 million in milestones from it and low royalties... so in the next 3-6 months a lot of upside
Advertisement
Advertisement